Skip to main content
logo
Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
4.690
+0.150 (3.30%)
Aug 6, 2026, 9:48 AM EDT - Market open

Prelude Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-12.147---
Revenue Growth
-73.43%----
Gross Profit
-12.147---
Operating Income
-84.14-104.57-139.71-132.28-123.54-113.74
Net Income
-77.8-99.5-127.17-121.83-115.44-111.69
Earnings Per Share
-1.00-1.29-1.68-2.02-2.44-2.43
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
81.55103.21133.61232.94201.73291.23
Total Debt
17.7217.7918.0320.231.831.74
Net Cash (Debt)
63.8385.43115.59212.71199.9289.49
Net Cash Growth
-21.34%-26.10%-45.66%6.41%-30.95%32.61%
Net Cash Per Share
0.811.111.523.524.226.29

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-43.76-56.3-102.89-107.06-83.73-83.53
Capital Expenditures
-0.02-0.07-0.76-3.51-3.02-2.32
Free Cash Flow
-43.78-56.37-103.65-110.58-86.75-85.85
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-100.00%100.00%---
Operating Margin
--861.33%-1995.91%---
Pretax Margin
--819.59%-1816.76%---
Profit Margin
--819.59%-1816.76%---
FCF Margin
--464.32%-1480.74%---

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
26.9315.0410.01---